Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.49 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.46 |
| ▸ | NOS2 | P35228 | 6/20 | 0.44 |
| ▸ | NOS3 | P29474 | 5/20 | 0.44 |
| ▸ | NOS1 | P29475 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ARG1 | P05089 | 3/20 | 0.39 |
| ▸ | ARG2 | P78540 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL453745 | 1.00 | OTC (0.49) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL6671444 | 1.00 | OTC (0.49) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL5698936 | 1.00 | OTC (0.49) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL1898345 | 1.00 | OTC (0.49) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL1898346 | 1.00 | OTC (0.49) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL263652 | 1.00 | OTC (0.49) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL288808 | 1.00 | OTC (0.49) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL6946785 | 1.00 | OTC (0.49) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL20946267 | 1.00 | OTC (0.49) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL9537954 | 0.95 | OTC (0.46) | OTCDDAH1NOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024105205-A1 | ANTIBODY-DRUG CONJUGATES (A2DCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-23 | — | — | WO | disclosed |
| US-11865195-B2 | Evaluation of presence of and vulnerability to atrial fibrillation and other indications using matrix metalloproteinase-based imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| WO-2023195447-A1 | EVALUATION METHOD, CALCULATION METHOD, EVALUATION DEVICE, CALCULATION DEVICE, EVALUATION PROGRAM, CALCULATION PROGRAM, RECORDING MEDIUM, EVALUATION SYSTEM AND TERMINAL DEVICE FOR RELATIVE PHARMACOLOGICAL ACTION OF COMBINATION OF IMMUNE CHECKPOINT INHIBITOR WITH ANTICANCER DRUG AS CONCOMITANT DRUG COMPARED TO PHARMACOLOGICAL ACTION OF IMMUNE CHECKPOINT INHIBITOR ALONE | 味の素株式会社 | 2023-10-12 | — | — | WO | disclosed |
| WO-2020255743-A1 | EVALUATION METHOD FOR FOOD RELATED TO COGNITIVE FUNCTION | 味の素株式会社 | 2020-12-24 | — | — | WO | disclosed |
| US-20200390912-A1 | EVALUATION OF PRESENCE OF AND VULNERABILITY TO ATRIAL FIBRILLATION AND OTHER INDICATIONS USING MATRIX METALLOPROTEINASE-BASED IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2020-12-17 | — | — | US | disclosed |
| WO-2020203878-A1 | EVALUATING METHOD, CALCULATING METHOD, EVALUATING DEVICE, CALCULATING DEVICE, EVALUATING PROGRAM, CALCULATING PROGRAM, STORAGE MEDIUM, EVALUATING SYSTEM, AND TERMINAL DEVICE OF AMYLOID BETA ACCUMULATION IN BRAIN | 味の素株式会社 | 2020-10-08 | — | — | WO | disclosed |
| WO-2020184660-A1 | METHOD FOR EVALUATING SARCOPENIA, CALCULATION METHOD, EVALUATION DEVICE, CALCULATION DEVICE, EVALUATION PROGRAM, CALCULATION PROGRAM, RECORDING MEDIUM, EVALUATION SYSTEM, AND TERMINAL DEVICE | 味の素株式会社 | 2020-09-17 | — | — | WO | disclosed |
| WO-2020158828-A1 | METHOD FOR EVALUATING FUTURE RISK OF OCCURRENCE OF CEREBRAL AND CARDIOVASCULAR EVENT, CALCULATION METHOD, EVALUATION DEVICE, CALCULATION DEVICE, EVALUATION PROGRAM, CALCULATION PROGRAM, STORAGE MEDIUM, EVALUATION SYSTEM, AND TERMINAL DEVICE | 味の素株式会社 | 2020-08-06 | — | — | WO | disclosed |
| WO-2020067386-A1 | MILD-COGNITIVE-IMPAIRMENT EVALUATION METHOD, CALCULATION METHOD, EVALUATION DEVICE, CALCULATION DEVICE, EVALUATION PROGRAM, CALCULATION PROGRAM, RECORDING MEDIUM, EVALUATION SYSTEM, AND TERMINAL DEVICE | 味の素株式会社 | 2020-04-02 | — | — | WO | disclosed |
| WO-2019198601-A1 | METHOD, DEVICE AND PROGRAM FOR EVALUATING HEALTH STATUS AND/OR GROWTH STATUS OF LIVESTOCK | 味の素株式会社 | 2019-10-17 | — | — | WO | disclosed |
| EP-0692982-A1 | RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-24 | — | — | EP | disclosed |
| EP-0691987-A1 | CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-17 | — | — | EP | disclosed |
| US-5430151-A | Treatment of aids, pneumonia, caprine arthritis encephalitis, leukemia and immmunodeficiency | BAYER AKTIENGESELLSCHAFT (DE) | 1995-07-04 | — | — | US | disclosed |
| US-5424426-A | Dithiolanylglycine-containing HIV protease inhibitors of the hydroxyethylene isostere type | BAYER AKTIENGESELLSCHAFT (DE) | 1995-06-13 | — | — | US | disclosed |
| WO-1995001993-A1 | COMPOUNDS HAVING THE ANTIGENICITY OF hCG | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1995-01-19 | — | — | WO | disclosed |
| US-5369038-A | Diagnosis of thrombotic diseases | TEIJIN LIMITED (JP) | 1994-11-29 | — | — | US | disclosed |
| EP-0625164-A1 | CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-11-23 | — | — | EP | disclosed |
| US-5364931-A | Phosphonate-containing pseudopeptides of the hydroxyethylamine and norstatin type | BAYER AKTIENGESELLSCHAFT (DE) | 1994-11-15 | — | — | US | disclosed |
| US-5147865-A | Viricides | BAYER AKTIENGESELLSCHAFT (DE) | 1992-09-15 | — | — | US | disclosed |
| US-5145951-A | Protected ologopeptides; treating aids | BAYER AKTIENGESELLSCHAFT, A CORP. OF GERMANY (DE) | 1992-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11865195-B2 | Evaluation of presence of and vulnerability to atrial fibrillation and other indications using matrix metalloproteinase-based imaging | MMP3, MMP1, TIMP3 | OTC 2985/4885DDAH1 794/4885NOS2 527/4885 |
| US-20200390912-A1 | EVALUATION OF PRESENCE OF AND VULNERABILITY TO ATRIAL FIBRILLATION AND OTHER INDICATIONS USING MATRIX METALLOPROTEINASE-BASED IMAGING | MMP3, MMP1, TIMP3 | OTC 2985/4885DDAH1 794/4885NOS2 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.